Sectoral Asset Management

Pipeline Therapeutics Inc. develops and commercializes small molecules for neuroregeneration, including synaptogenesis, remyelination, and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of earlier stage programs, including PIPE-307, focused on remyelination and axonal repair to address a range of neurological disorders, including multiple sclerosis. The company was founded in 2017 and is based in San Diego, California.

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.

Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases.

HighLife SAS, a medtech company, develops novel transcatheter mitral valve replacement system for treating patients suffering from mitral regurgitation. It focuses on providing a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. The company was founded in 2010 and is based in Paris, France with an additional office in Irvine, California.

Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases.

BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.

Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders. Sleep apnea is a common, serious condition with significant morbidity, increased mortality, and substantial effects on daily functioning. Sleep apnea affects more than 20 million Americans and has serious consequences. OSA is caused by a combination of predisposing anatomical factors and sleep-related decrements of activity in upper airway muscles. Current treatments primarily rely on positive pressure devices, e.g., CPAP, to maintain airway patency. Less commonly used treatments include mandibular advancement devices, nerve stimulation, and surgical interventions. Apnimed, Inc. was founded in 2017 and is located in Cambridge, Massachusetts.

Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.

Magnolia Medical Technologies is a device development company that focuses on improving the accuracy of diagnostic blood culture tests. It has developed a wide range of products to significantly improve diagnostic specimen quality aimed at directly and dramatically increasing diagnostic accuracy for critical laboratory tests. The company’s intellectual property portfolio includes more than 70 issued patents with more than 50 additional patent applications pending. It was incorporated in 2011 and is based in Seattle, Washington.

Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.

REGENX Biosciences, LLC, a biopharmaceutical company, develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia.

Apellis Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (COPD). Apellis emerged from a successful transaction between Potentia Pharmaceuticals, Inc. and Alcon Research, Ltd in October 2009 in which Alcon licensed the ocular applications of Potentia’s family of complement inhibitors. Apellis holds the worldwide exclusive rights to the extra-ocular uses of these compounds. In May 2010, with start-up capital raised from private investors, Apellis commenced full-scale operations.

Rainier Therapeutics, Inc., a biotechnology company, develops a targeted biologic for the potential treatment of early stage and metastatic bladder cancer. It offers Vofatamab (B-701), a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3) that is used for the treatment for metastatic bladder cancer. Rainier Therapeutics, Inc. was formerly known as BioClin Therapeutics, Inc. and changed its name to Rainier Therapeutics, Inc. in November 2018. The company was founded in 2010 and is based in San Leandro, California.

Prilenia Therapeutics B.V., a clinical stage biotech company, researches and develops products for movement disorders and neurodegenerative diseases affecting adults and children. It offers Pridopidine, an orally bioavailable small molecule investigational drug for huntington disease, amyotrophic lateral sclerosis, Parkinson’s disease levodopa induced dyskinesia, neurodegenerative eye disease, Parkinson’s disease, rett syndrome, fragile X, and Alzheimer’s disease. The company was founded in 2018 and is based in the Netherlands.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.

Babylon Healthcare Services Limited operates a subscription based mobile healthcare application. Its platform allows users to book a virtual general practitioner (GP) consultation with clinicians, have a remote consultation, and collect relevant prescriptions. Babylon Healthcare Services Limited was founded in 2013 and is based in London, United Kingdom with additional offices in Brooklyn, New York; Austin, Texas; Kigali, Rwanda; Vancouver, Canada; Kuala Lumpur, Malaysia; and Singapore.

Turnstone Biologics Inc., a biotechnology company, focuses on the development of viral immunotherapies to improve survival of people with cancer. Its lead candidate RIVAL-01 consists of the vaccinia virus backbone encoding three potent immunomodulators, such as Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine designed to work together to drive immune activity and re-program the microenvironment to be best suited for tumor eradication. The company was founded in 2015 and is based in Ottawa, Canada with an additional office in New York, New York.

eFFECTOR Therapeutics is an early stage company focused on the discovery and development of new small molecule cancer therapeutics. eFFECTOR is developing translation regulators to selectively block disregulated translation impacting tumor growth and survival. The company has selected control of mRNA translation as a key point of theerapeutic intervention, providing potency and selectivity while inhibiting growth of cancer cells. eFFECTOR's novel approach provides a real opportunity to bring innovative new medicines to patients in need.

Pipeline Therapeutics Inc. develops and commercializes small molecules for neuroregeneration, including synaptogenesis, remyelination, and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of earlier stage programs, including PIPE-307, focused on remyelination and axonal repair to address a range of neurological disorders, including multiple sclerosis. The company was founded in 2017 and is based in San Diego, California.

Simplify Medical designs, develops, and manufactures cervical artificial discs for use in the spine. It offers an MRI compatible motion preserving artificial cervical disc that is used to treat single level symptomatic cervical disc disease. The company provides its products for skeletally mature patients for reconstruction of the disc at one level from C3-C7 following single-level discectomy for intractable radiculopathy, such as arm pain or a neurological deficit. Simplify Medical was founded in 2015 and is based in Mountain View, California.

Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses. Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.

Neuros Medical, Inc., a neuromodulation company, develops proprietary neurostimulation therapies for unmet needs to patients worldwide. It offers Electrical Nerve Block, a technology for the elimination of chronic pain in various applications, including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine. The company also provides Neuros Altius System, a product that consists of an implantable generator with an integrated rechargeable battery, cuff electrode, and external devices. Neuros Medical, Inc. was incorporated in 2008 and is based in Willoughby Hills, Ohio.

Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.

Prilenia Therapeutics B.V., a clinical stage biotech company, researches and develops products for movement disorders and neurodegenerative diseases affecting adults and children. It offers Pridopidine, an orally bioavailable small molecule investigational drug for huntington disease, amyotrophic lateral sclerosis, Parkinson’s disease levodopa induced dyskinesia, neurodegenerative eye disease, Parkinson’s disease, rett syndrome, fragile X, and Alzheimer’s disease. The company was founded in 2018 and is based in the Netherlands.

CurvaFix, Inc., a medical device company, develops products for pelvic fracture repair. It offers The CurvaFix, an intramedullary rod screw that follows the natural bone shape and fills the space within curved bones, such as the pelvis. CurvaFix, Inc. was founded in 2017 and is based in Bellevue, Washington.

Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, MA.

Aprea AB is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicle owned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. Other shareholders include Östersjöstiftelsen, Praktikerinvest, and KCIF Co-Investment Fund KB.

HemaQuest Pharmaceuticals, Inc. provides pharmaceutical products. The Company develops small molecule therapeutics to treat serious and life threatening hematologic disorders, including anemia, beta thalassemia, sickle cell anemia, and neutropenia. HemaQuest Pharmaceuticals operates in the United States.

Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.

Simplify Medical designs, develops, and manufactures cervical artificial discs for use in the spine. It offers an MRI compatible motion preserving artificial cervical disc that is used to treat single level symptomatic cervical disc disease. The company provides its products for skeletally mature patients for reconstruction of the disc at one level from C3-C7 following single-level discectomy for intractable radiculopathy, such as arm pain or a neurological deficit. Simplify Medical was founded in 2015 and is based in Mountain View, California.

ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.

Aprea AB is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicle owned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. Other shareholders include Östersjöstiftelsen, Praktikerinvest, and KCIF Co-Investment Fund KB.

Pipeline Therapeutics Inc. develops and commercializes small molecules for neuroregeneration, including synaptogenesis, remyelination, and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of earlier stage programs, including PIPE-307, focused on remyelination and axonal repair to address a range of neurological disorders, including multiple sclerosis. The company was founded in 2017 and is based in San Diego, California.

eFFECTOR Therapeutics is an early stage company focused on the discovery and development of new small molecule cancer therapeutics. eFFECTOR is developing translation regulators to selectively block disregulated translation impacting tumor growth and survival. The company has selected control of mRNA translation as a key point of theerapeutic intervention, providing potency and selectivity while inhibiting growth of cancer cells. eFFECTOR's novel approach provides a real opportunity to bring innovative new medicines to patients in need.

RainDance Technologies is making complex genetics simple. The company’s ultra-sensitive genomic tools enable better research of novel non-invasive Fluid Biopsy™ applications that should result in more accurate, reliable, cost-effective and early detection of cancer, inherited and infectious diseases. Major research institutions and laboratories around the world rely on RainDance systems’ performance. Based in Billerica, Massachusetts, the company supports customers using RainDrop Digital PCR and ThunderStorm Targeted Next-Generation Sequencing Systems through its international sales and service operations as well as a global network of distributors and commercial service providers.

Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.

F2G Ltd develops novel therapies to treat fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent. The company offers orotomides that are antifungal agents against Aspergillus and other filamentous molds. F2G Ltd was formerly known as Functional Fungal Genomics Ltd and changed its name to F2G Ltd in July 1999. F2G Ltd was founded in 1998 and is based in Manchester, United Kingdom.

Intellia Therapeutics was formed in 2014 to lead the industry in one of the most promising new areas of therapeutic development: gene editing and repair using CRISPR-Cas9 technology. Intellia holds exclusive access to one of the most comprehensive intellectual property platforms available for the therapeutic use of CRISPR-Cas9. The company is advancing a broad pipeline toward clinical development, including ex vivo and in vivo approaches. Intellia closed a Series A round in 2014 led by Atlas Venture and Novartis.

eFFECTOR Therapeutics is an early stage company focused on the discovery and development of new small molecule cancer therapeutics. eFFECTOR is developing translation regulators to selectively block disregulated translation impacting tumor growth and survival. The company has selected control of mRNA translation as a key point of theerapeutic intervention, providing potency and selectivity while inhibiting growth of cancer cells. eFFECTOR's novel approach provides a real opportunity to bring innovative new medicines to patients in need.

Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.